Life Science Nation Newsletter | March 3, 2016 | Issue 152
|
|
 Life Science Investor Mandates (Feb. 25 - Mar. 2) |
| |
|
Seeks USA Drug Platform Startups
|
Invests in Early Therapeutic Platforms and Revenue-Generating Medtech or Healthcare IT
|
|
Seeks Innovative Antibiotics
|
|
Seeks Devices & Diagnostics in Women's Health
|
|
|
  Nature Magazine has published an article written by Dennis Ford (CEO) and Bill Kohlbrenner (CSO) that draws upon LSN's expertise to provide practical guidance on capital raising for early stage life science companies.
If you are an aspiring entrepreneur spinning out a new biomedical technology or launching a biotech startup, one of your first tasks is to understand the funding process and how to tackle it...
|
 |
|
|
By Nono Hu, Director of Marketing, LSN
 What does it cost to raise capital? In LSN's experience, one signal that consistently distinguishes a company that is committed to raising capital is that the company has a realistic plan and budget for their fundraising campaign. And when a company has a budget, it's vital to ensure that they're getting the most return on investment (ROI) possible from their campaign expenses.
That's where the Redefining Early Stage Investments (RESI) Conference fits in. As a one-day event with a 1:1 ratio of investors to startup companies, RESI inundates attendees with opportunities to connect...
|
|
|
Startups can now benefit from both grants and R&D Tax Credits
The R&D Tax Credit was created by Congress to encourage R&D investment within the United States. In the past, however, R&D credits were only available to companies that are profitable, as companies that have yet to turn a profit had no tax burden to be reduced by the credits. It seemed unfair that life science startups, which primarily perform R&D but typically pay no income tax for years, could not benefit from the R&D Tax Credit...
|
|
|
|
|
